Aldosterone and myocardial infarction--are aldosterone antagonists needed to prevent remodelling or does ACE inhibition suffice?
Remme
W J
WJ
D000450:Aldosterone / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002191:Canrenoic Acid / Q000627:therapeutic use; D002216:Captopril / Q000627:therapeutic use; D006332:Cardiomegaly / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D000450:Aldosterone; D002191:Canrenoic Acid; D002216:Captopril; D007703:Peptidyl-Dipeptidase A